Iovance Biotherapeutics Financial Statements
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Iovance Biotherapeutics revenue and earnings
In fiscal 2025, Iovance Biotherapeutics generated $263.5 million in revenue, up 60.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Iovance Biotherapeutics reported a net loss of $391.0 million, compared with a loss of $372.2 million a year earlier. Gross margin was 34.3% (down from 43.2%) and operating margin -153.1%.
Diluted earnings per share came in at -$1.09.
Summary generated from market data by MetaCap's automated system. Methodology
Iovance Biotherapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 263.50M | 164.07M | 1.19M | — | — | — | — | 0 | 0 | 0 |
| Revenue growth (YoY) | +60.60% | +13698.99% | — | — | — | — | — | — | — | — |
| Cost of Revenue | 173.18M | 93.25M | 1.03M | — | — | — | — | — | — | — |
| Gross Profit | 90.32M | 70.82M | 156.00K | — | — | — | — | — | — | — |
| Operating Expenses | 493.67M | 466.10M | 460.71M | 398.88M | 342.70M | 261.94M | 206.87M | 128.26M | 92.88M | 53.64M |
| Research & Development | 300.27M | 276.23M | 333.19M | 294.78M | 259.04M | 201.73M | 166.02M | 99.83M | 71.61M | 26.94M |
| Operating Income | -403.36M | -395.28M | -460.56M | -398.88M | -342.70M | -261.94M | -206.87M | -128.26M | -92.88M | -53.64M |
| Pretax Income | -393.05M | -375.00M | -447.52M | -395.89M | -342.25M | — | — | — | — | — |
| Income Tax | -2.07M | -2.83M | -3.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -390.98M | -372.18M | -444.04M | -395.89M | -342.25M | -259.58M | -197.56M | -123.58M | -92.06M | -52.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 | -1.27 | -1.41 | -1.85 |
| EPS (Diluted) | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 | -1.27 | -1.41 | -1.85 |
| Shares Outstanding (Basic) | 357.35K | 289.88K | 235.13K | 159.26K | 153.41K | 138.30K | 124.34K | 97.28K | 65.24K | 55.27K |
| Shares Outstanding (Diluted) | 357.35K | 289.88K | 235.13K | 159.26K | 153.41K | 138.30K | 124.34K | 97.28K | 65.24K | 55.27K |
| EBITDA | -390.49M | -384.02M | -448.99M | -389.57M | -339.59M | -260.80M | -205.70M | -127.30M | -91.92M | -52.66M |
| Gross Margin | 34.28% | 43.17% | 13.12% | — | — | — | — | — | — | — |
| Operating Margin | -153.08% | -240.92% | -38734.99% | — | — | — | — | — | — | — |
| Net Margin | -148.38% | -226.84% | -37345.42% | — | — | — | — | — | — | — |
This table shows 10 annual periods of Iovance Biotherapeutics's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow IOVA's reporting calendar. What is a income statement?